> top > docs > PMC:7205724 > spans > 22431-22936 > annotations

PMC:7205724 / 22431-22936 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
788 172-175 Gene denotes IL6 Gene:3569
789 355-358 Gene denotes CRP Gene:1401
790 22-30 Species denotes patients Tax:9606
791 148-156 Species denotes Patients Tax:9606
792 416-424 Species denotes patients Tax:9606
793 113-124 Chemical denotes Tocilizumab MESH:C502936
794 212-223 Chemical denotes tocilizumab MESH:C502936
795 289-295 Chemical denotes oxygen MESH:D010100
796 483-494 Chemical denotes tocilizumab MESH:C502936
797 36-44 Disease denotes COVID-19 MESH:C000657245
798 373-384 Disease denotes lung lesion MESH:D008171
799 462-468 Disease denotes deaths MESH:D003643

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T164 329-339 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T165 373-377 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T23 373-377 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T177 36-44 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T267 14-16 http://purl.obolibrary.org/obo/CLO_0050509 denotes 27
T268 165-166 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T269 199-201 http://purl.obolibrary.org/obo/CLO_0008426 denotes pg
T270 373-377 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T271 373-377 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T171 212-223 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360
T172 289-295 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805
T173 483-494 Chemical denotes tocilizumab http://purl.obolibrary.org/obo/CHEBI_64360

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T22 289-324 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes oxygen saturation and normalization http://purl.bioontology.org/ontology/MEDDRA/10033322

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T102 265-273 http://purl.obolibrary.org/obo/OGMS_0000020 denotes symptoms

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T110 289-295 Chemical denotes oxygen http://purl.obolibrary.org/obo/CHEBI_25805

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T218 36-44 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T183 0-147 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 148-366 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 367-425 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 426-505 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T23 373-377 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
790 22-30 Species denotes patients Tax:9606
797 36-44 Disease denotes COVID-19 MESH:C000657245
793 113-124 Chemical denotes Tocilizumab MESH:C502936
791 148-156 Species denotes Patients Tax:9606
788 172-175 Gene denotes IL6 Gene:3569
794 212-223 Chemical denotes tocilizumab MESH:C502936
795 289-295 Chemical denotes oxygen MESH:D010100
789 355-358 Gene denotes CRP Gene:1401
798 373-384 Disease denotes lung lesion MESH:D008171
792 416-424 Species denotes patients Tax:9606
799 462-468 Disease denotes deaths MESH:D003643
796 483-494 Chemical denotes tocilizumab MESH:C502936

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T2161 172-175 Protein denotes IL6 https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0
T2205 355-358 Protein denotes CRP https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T21073 0-2 IN denotes In
T65150 3-6 DT denotes the
T61991 7-12 NN denotes study
T18474 13-14 -LRB- denotes [
T8341 14-16 CD denotes 27
T6430 16-17 -RRB- denotes ]
T29393 17-18 -COMMA- denotes ,
T77821 19-21 CD denotes 21
T79215 22-30 NNS denotes patients
T5404 31-35 IN denotes with
T75582 36-44 NN denotes COVID-19
T89299 45-50 WP-DOLLAR- denotes whose
T66055 51-60 NN denotes condition
T80340 61-64 VBD denotes was
T3490 65-71 JJ denotes severe
T44653 72-74 CC denotes or
T55941 75-83 JJ denotes critical
T85453 84-92 VBD denotes received
T98598 93-96 CD denotes one
T96881 97-99 CC denotes or
T24534 100-103 CD denotes two
T70238 104-109 NNS denotes doses
T20616 110-112 IN denotes of
T68912 113-124 NNP denotes Tocilizumab
T98192 125-129 CC denotes plus
T20706 130-138 JJ denotes standard
T58005 139-146 NN denotes therapy
T96625 148-156 NNS denotes Patients
T75572 157-160 WP denotes who
T31917 161-164 VBD denotes had
T15301 165-166 DT denotes a
T24848 167-171 JJ denotes mean
T84688 172-175 NN denotes IL6
T96963 176-181 NN denotes level
T6930 182-184 IN denotes of
T90933 185-189 JJR denotes more
T81944 190-194 IN denotes than
T75581 195-204 NN denotes 100 pg/ml
T64021 205-211 IN denotes before
T9387 212-223 NN denotes tocilizumab
T84664 224-233 NN denotes treatment
T18203 234-240 VBD denotes showed
T60803 241-252 NN denotes improvement
T44490 253-255 IN denotes in
T81402 256-264 JJ denotes clinical
T14228 265-273 NNS denotes symptoms
T94537 274-277 CC denotes and
T83697 278-288 JJ denotes peripheral
T13978 289-295 NN denotes oxygen
T35808 296-306 NN denotes saturation
T34900 307-310 CC denotes and
T75964 311-324 NN denotes normalization
T84268 325-328 IN denotes for
T65028 329-339 NN denotes lymphocyte
T34390 340-350 NN denotes proportion
T96610 351-354 CC denotes and
T30755 355-358 NN denotes CRP
T63070 359-365 NNS denotes levels
T31791 367-371 RB denotes Also
T31152 371-372 -COMMA- denotes ,
T79595 373-377 NN denotes lung
T51431 378-384 NN denotes lesion
T10130 385-392 NN denotes opacity
T31388 393-396 VBD denotes was
T1824 397-405 VBN denotes absorbed
T60055 406-408 IN denotes in
T38598 409-411 CD denotes 90
T67288 411-412 NN denotes %
T48683 413-415 IN denotes of
T41529 416-424 NNS denotes patients
T69670 426-433 CC denotes Neither
T9277 434-441 JJ denotes serious
T15021 442-449 JJ denotes adverse
T23626 450-457 NNS denotes effects
T98539 458-461 CC denotes nor
T65699 462-468 NNS denotes deaths
T50204 469-477 VBD denotes occurred
T20973 478-482 IN denotes with
T14012 483-494 NN denotes tocilizumab
T66286 495-504 NN denotes treatment
R75326 T85453 T21073 arg1Of received,In
R27739 T61991 T21073 arg2Of study,In
R82994 T61991 T65150 arg1Of study,the
R48681 T61991 T18474 arg1Of study,[
R80450 T8341 T18474 arg2Of 27,[
R99891 T6430 T18474 arg3Of ],[
R98220 T85453 T29393 arg1Of received,","
R79228 T79215 T77821 arg1Of patients,21
R3039 T79215 T5404 arg1Of patients,with
R31375 T75582 T5404 arg2Of COVID-19,with
R14004 T66055 T89299 arg1Of condition,whose
R84172 T75582 T89299 arg2Of COVID-19,whose
R52999 T66055 T80340 arg1Of condition,was
R29264 T44653 T80340 arg2Of or,was
R90654 T66055 T3490 arg1Of condition,severe
R25403 T3490 T44653 arg1Of severe,or
R81194 T55941 T44653 arg2Of critical,or
R78022 T66055 T55941 arg1Of condition,critical
R74963 T79215 T85453 arg1Of patients,received
R42123 T70238 T85453 arg2Of doses,received
R67132 T70238 T98598 arg1Of doses,one
R74424 T98598 T96881 arg1Of one,or
R53734 T24534 T96881 arg2Of two,or
R5731 T70238 T24534 arg1Of doses,two
R65601 T70238 T20616 arg1Of doses,of
R56743 T98192 T20616 arg2Of plus,of
R89899 T68912 T98192 arg1Of Tocilizumab,plus
R61440 T58005 T98192 arg2Of therapy,plus
R97353 T58005 T20706 arg1Of therapy,standard
R37793 T96625 T75572 arg1Of Patients,who
R91228 T96625 T31917 arg1Of Patients,had
R53068 T96963 T31917 arg2Of level,had
R75826 T96963 T15301 arg1Of level,a
R53187 T96963 T24848 arg1Of level,mean
R88261 T96963 T84688 arg1Of level,IL6
R96088 T96963 T6930 arg1Of level,of
R5373 T90933 T6930 arg2Of more,of
R57258 T90933 T81944 arg1Of more,than
R94369 T75581 T81944 arg2Of 100 pg/ml,than
R45661 T90933 T64021 arg1Of more,before
R79916 T84664 T64021 arg2Of treatment,before
R78642 T84664 T9387 arg1Of treatment,tocilizumab
R8185 T96625 T18203 arg1Of Patients,showed
R51850 T94537 T18203 arg2Of and,showed
R12091 T60803 T44490 arg1Of improvement,in
R66809 T14228 T44490 arg2Of symptoms,in
R61551 T14228 T81402 arg1Of symptoms,clinical
R5554 T60803 T94537 arg1Of improvement,and
R21619 T34900 T94537 arg2Of and,and
R92393 T35808 T83697 arg1Of saturation,peripheral
R24887 T35808 T13978 arg1Of saturation,oxygen
R90774 T35808 T34900 arg1Of saturation,and
R67692 T75964 T34900 arg2Of normalization,and
R62752 T34900 T84268 arg1Of and,for
R8244 T63070 T84268 arg2Of levels,for
R10896 T63070 T65028 arg1Of levels,lymphocyte
R57903 T63070 T34390 arg1Of levels,proportion
R97168 T34390 T96610 arg1Of proportion,and
R13130 T30755 T96610 arg2Of CRP,and
R88299 T63070 T30755 arg1Of levels,CRP
R81985 T1824 T31791 arg1Of absorbed,Also
R90910 T1824 T31152 arg1Of absorbed,","
R99138 T10130 T79595 arg1Of opacity,lung
R9904 T10130 T51431 arg1Of opacity,lesion
R90450 T10130 T31388 arg1Of opacity,was
R27294 T1824 T31388 arg2Of absorbed,was
R44975 T10130 T1824 arg2Of opacity,absorbed
R49421 T1824 T60055 arg1Of absorbed,in
R89954 T67288 T60055 arg2Of %,in
R85705 T67288 T38598 arg1Of %,90
R91084 T67288 T48683 arg1Of %,of
R76104 T41529 T48683 arg2Of patients,of
R22449 T98539 T69670 arg1Of nor,Neither
R42879 T98539 T9277 arg1Of nor,serious
R85183 T98539 T15021 arg1Of nor,adverse
R27191 T23626 T98539 arg1Of effects,nor
R64318 T65699 T98539 arg2Of deaths,nor
R37231 T98539 T50204 arg1Of nor,occurred
R56159 T50204 T20973 arg1Of occurred,with
R79941 T66286 T20973 arg2Of treatment,with
R50965 T66286 T14012 arg1Of treatment,tocilizumab

LitCovid-sample-PD-MAT

Id Subject Object Predicate Lexical cue
T7 373-377 http://purl.obolibrary.org/obo/MAT_0000135 denotes lung

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T164 329-339 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T165 373-377 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T167 36-44 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T183 0-147 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 148-366 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 367-425 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 426-505 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.